Will ALC's Q1 2025 earnings beat forecasts?

**Alcon's Q1 2025 earnings are likely to beat forecasts**, considering the following points: 1. **Strong Performance in Recent Months**: Alcon's shares have seen a significant increase, ending a trading session 6% higher at $96.80, driven by optimism surrounding its aggressive M&A activity. This strong price increase suggests market confidence in the company's prospects. 2. **Earnings and Revenue Estimates**: The estimated EPS for Q1 2025 is $0.76, and the estimated revenue is $2.53 billion. Alcon's actual EPS and revenue figures may exceed these estimates due to the company's strong recent performance and product launch expectations. 3. **Product Launches and Market Potential**: Alcon is preparing for a significant wave of product launches in 2025, including the UNITY VCS surgical platform and the Voyager laser trabeculoplasty device. These innovations are expected to contribute to the company's growth and potentially boost earnings in Q1 2025. 4. **Financial Outlook and Market Confidence**: Alcon has projected full-year revenue growth of 6% to 8% on a constant currency basis for 2025, with sales expected between $10.2 billion and $10.4 billion. This guidance is in line with market expectations and suggests a positive outlook for the company's earnings in the upcoming quarter. 5. **Historical Performance and Trends**: Alcon's historical performance and trends in earnings estimate revisions suggest that the company's earnings are poised to exceed forecasts. The consensus EPS estimate for Q1 2025 has not been revised downward, and the stock carries a Zacks Rank #3 (Hold), indicating a potential for price appreciation. In conclusion, considering Alcon's recent performance, product launches, financial outlook, and market confidence, it is reasonable to expect that the company's Q1 2025 earnings may exceed forecasts.